Dr. Amy Hauck Newman has published 245 peer-reviewed manuscripts and is widely regarded as an expert in the field of medicinal chemistry. She currently serves as Deputy Scientific Director of the National Institute on Drug Abuse (NIDA) Intramural Research Program and Chief of the Medications Discovery Research Branch and Medicinal Chemistry Sections of NIDA. She has designed several research tools to better evaluate drug-receptor interactions and study how molecular changes influence behavior. In recent years, her lab has synthesized novel compounds that target monoamine transporters and receptors to treat addictions. She is the lead inventor of EncepHeal's first pharmacotherapies to treat cocaine addiction.
Dr. Newman earned her B.S. in Chemistry from Mary Washington College and her Ph.D. in Medicinal Chemistry from the Medical College of Virginia where she designed and synthesized novel amphetamine analogs. Dr. Newman completed her postdoctoral training under Dr. Kenner C. Rice at the Laboratory of Medicinal Chemistry at the NIH and worked at the Walter Reed Army Institute of Research before she initiated the Medicinal Chemistry Program at NIDA.
to Heal the Mind
Dr. Strachan previously served as Senior Scientist II in the Medicinal Chemistry Department for the biopharmaceutical company Targacept, Inc. During that time, he was the lead chemist on Targacept's Parkinson’s disease project team and advanced a lead compound for the treatment of L-Dopa-induced dyskinesias. Prior to joining Targacept, Dr. Strachan worked for several contract research organizations and biopharmaceutical companies in North Carolina. He obtained his Ph.D. in Organic Chemistry and B.Sc. in Chemistry from the University of Edinburgh in Scotland before finishing his postdoctoral work with Dr. Jon Lindsey at North Carolina State University.
Dr. Beaver currently serves as Senior Director, Regulatory Affairs and Quality Compliance for KeraNetics LLC. She brings over twelve years of research and development experience in the pharmaceutical industry, oversees regulatory affairs strategy, and manages the company's quality system.
Prior to joining Targacept, Dr. Beaver held positions of increased responsibility with Johnson & Johnson as Clinical Pharmacology lead on multiple programs for worldwide marketed products and candidates in development. She has also served as a professor at Temple University and The Pharmaceutical Education & Research Institute. Dr. Beaver holds a Ph.D. in Pharmaceutical Sciences and a B.S. in pharmacy, both from the University of North Carolina, Chapel Hill.
Dr. Martell has over 15 years of experience in the pharmaceutical/biotechnology industry as a drug developer, strategic advisor, and scientific consultant. She has deep expertise in therapeutic drug development and has brought complex protein biologics, biosimilars, combined drug devices, and therapeutic vaccines through various stages of development while being facile in understanding the Global Regulatory landscape and the requirements to bring medicines through to approval with the appropriate value to patients, physicians, and payers alike. She has work in varied therapeutic areas including oncology, immuno-oncology, rheumatology, pain, addiction, orphan diseases, CNS, cardiovascular, and women’s health. She is currently leading her consulting practice, BAM Consultants, LLC, where she has advised clients since 2013. From 2015 to present she served as the Senior Vice President of New Product Development and Chief Medical Officer of Juniper Pharmaceuticals, a public company with a focus on women’s health therapeutics. Currently, Dr. Martell still actively practices clinical internal medicine part-time at Yale and serves as an Entrepreneur-In-Residence for Yale’s Office of Cooperative Research helping guide Yale innovators on the prospects for their patented technologies, therapeutics, devices, and diagnostics. This work coupled with her deep industry experience adds value and perspective in understanding marketplace dynamics and continued unmet medical need.
Her prior work has included overseeing product development and medical affairs activities for numerous pharmaceutical companies, including Purdue Pharma and several business units within Pfizer Worldwide’s biopharmaceutical business. At Purdue Pharma, Dr. Martell led and built a new medical affairs organization to support the in-line and developing pain medicines. As the Biosimilars Medical Head at Pfizer, she was responsible for clinical development and medical affairs activities of the portfolio in that newly created business. She also held senior clinical development roles at other business units within Pfizer’s biopharmaceutical businesses. She began her clinical investigation career at Yale with a Career Development Award and as a Faculty Auditor in the Robert Wood Johnson Clinical Scholar conducting the first therapeutic cocaine vaccine trial for adjunctive treatment for cocaine dependence.
Dr. Martell holds a Bachelor of Science in microbiology from Cornell University, a Master of Arts in molecular immunology from Boston University, and a Doctor of Medicine degree from The Chicago Medical School. She completed her internship and residency in internal medicine, was also an Internal Medicine Chief Resident. She is board certified in both internal and addiction medicine.
Dr. Childers, has published more than 150 peer-reviewd manuscripts on the neuropharmacological and biochemical mechanisms of drugs of abuse including psychostimulants, cannabinoids, and opioids as well as the mechanisms of chronic drug actions on the brain. He is widely regarded as an expert in the field of biochemical neuropharmacology.
In 1999, Dr. Childers served as a member of the panel of scientific experts that generated the report on Marijuana and Medicine for the Institute of Medicine, National Academy of Sciences. He has served as a Member of Scientific Advisory Board at Ventaira Pharmaceuticals, Inc. since 2007.
Dr. Childers currently serves as Director of the Center for the Neurobiology of Addiction Treatment, funded by the National Institute on Drug Abuse (NIDA), and as Professor in the Department of Physiology & Pharmacology at Wake Forest School of Medicine. He earned his B.S. in chemistry from the University of Texas at Austin in 1972 and his Ph.D. in physiological chemistry from the University of Wisconsin in 1976 before completing a postdoctoral fellowship under Dr. Solomon Snyder at Johns Hopkins University in 1979.